Chlorzoxazone/acetaminophen
Executive Summary
FDA notifies 62 firms through July 27 reg letter to cease marketing the skeletal muscle relaxant combination product pursuant to an April 27 Federal Register notice withdrawing portions of the NDA that provides for Parafon Forte tablets (McNeil) containing chlorzoxazone 250 mg and acetominophen 300 mg. The action stems from a DESI ruling that the combination lacks substantial evidence of efficacy.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.